LD
BIIB icon

Lipe & Dalton’s Biogen BIIB Stock Holding History

Lipe & Dalton’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,005
Closed -$2.4M – 107
2021
Q4 		$2.4M Hold
10,005
– – 1.14% 32
2021
Q3 		$2.83M Sell
10,005
-70
-0.7% -$22.9K 1.45% 28
2021
Q2 		$3.49M Sell
10,075
-2,850
-22% -$863K 1.81% 20
2021
Q1 		$3.62M Sell
12,925
-10
-0.1% -$2.7K 2.01% 19
2020
Q4 		$3.17M Buy
12,935
+360
+3% +$92.9K 1.95% 23
2020
Q3 		$3.57M Buy
12,575
+1,035
+9% +$289K 2.48% 12
2020
Q2 		$3.09M Sell
11,540
-35
-0.3% -$10.5K 2.24% 18
2020
Q1 		$3.66M Sell
11,575
-245
-2% -$74.4K 3.1% 7
2019
Q4 		$3.51M Buy
11,820
+90
+0.8% +$25K 2.32% 16
2019
Q3 		$2.73M Sell
11,730
-284
-2% -$66.1K 1.99% 21
2019
Q2 		$2.81M Buy
12,014
+5
+0% +$1.16K 2.01% 21
2019
Q1 		$2.84M Sell
12,009
-4,135
-26% -$1.3M 2.09% 20
2018
Q4 		$4.86M Sell
16,144
-140
-0.9% -$44.7K 3.96% 5
2018
Q3 		$5.75M Buy
16,284
+145
+0.9% +$49.9K 3.93% 4
2018
Q2 		$4.68M Sell
16,139
-173
-1% -$48.6K 3.45% 7
2018
Q1 		$4.47M Buy
16,312
+80
+0.5% +$24.8K 3.2% 9
2017
Q4 		$5.17M Sell
16,232
-285
-2% -$91.4K 3.57% 8
2017
Q3 		$5.17M Sell
16,517
-45
-0.3% -$13.3K 3.64% 5
2017
Q2 		$4.49M Buy
16,562
+10
+0.1% +$2.64K 2.91% 11
2017
Q1 		$4.53M Sell
16,552
-430
-3% -$122K 3.28% 11
2016
Q4 		$4.82M Sell
16,982
-85
-0.5% -$25.2K 3.43% 7
2016
Q3 		$5.34M Buy
17,067
+890
+6% +$264K 3.58% 3
2016
Q2 		$3.91M Buy
+16,177
New +$4.26M 2.7% 11
2015
Q3 		– Sell
-627
Closed -$253K – 65
2015
Q2 		$253K Hold
627
– – 0.18% 62
2015
Q1 		$265K Hold
627
– – 0.18% 56
2014
Q4 		$213K Hold
627
– – 0.14% 63
2014
Q3 		$207K Buy
+627
New +$207K 0.14% 58

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Lipe & Dalton's BIIB Position: Q1 2022 in Review

Lipe & Dalton sold out of Biogen (BIIB) in Q1 2022, closing a stake of 10,005 shares — an estimated $2.4M sold.

Lipe & Dalton first reported a position in BIIB in Q3 2014 and held it in 27 quarters. The position peaked at $5.75M in Q3 2018. 951 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.

  • Lipe & Dalton reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
  • Lipe & Dalton sold 10,005 Biogen shares in Q1 2022, an estimated $2.4M.
  • Lipe & Dalton first reported a position in Biogen in Q3 2014 and held it in 27 quarters.
  • Lipe & Dalton's Biogen position peaked at $5.75M in Q3 2018.
  • 951 funds tracked by Wall St. Rank held Biogen as of Q1 2022.

Based on Lipe & Dalton's 13F filing for Q1 2022, filed 26 Apr 2022.